ATGGF (Actinogen Medical) Moat Score: 2/10 (As of Jun. 28, 2026)


What is Actinogen Medical Moat Score?

Actinogen Medical ATGGF Moat Score is 2 as of Jun. 28, 2026. The stock has 4 warning signs investors should review. Among 1,402 Biotechnology companies, Actinogen Medical ranks better than 58.06% on this metric.

Actinogen Medical has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Actinogen Medical has No Moat: Actinogen Medical Ltd has very weak competitive advantages. It lacks market leadership, significant intellectual property, and customer loyalty. The company operates in a highly competitive biotech sector with minimal regulatory barriers or pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Actinogen Medical might have No Moat - Very weak/transient advantages.

Actinogen Medical  (OTCPK:ATGGF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Actinogen Medical Moat Score Related Terms

ATGGF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Actinogen Medical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinogen Medical Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's Moat Score distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Actinogen Medical (ATGGF) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Actinogen Medical ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Actinogen Medical's Moat Score too high?
Actinogen Medical's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Actinogen Medical's value of 2 is 0% at this industry median. Based on the distribution chart, Actinogen Medical ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint.
How does Actinogen Medical's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Actinogen Medical ranks #588 out of 1402 companies for Moat Score. This puts Actinogen Medical in the upper half of its industry. The industry median Moat Score is 2.00. Actinogen Medical's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actinogen Medical's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actinogen Medical's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinogen Medical stock overvalued right now?
Actinogen Medical (ATGGF) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Actinogen Medical (ATGGF), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinogen Medical Business Description

Other Exchanges 3AC:GermanyACW:Australia
Address 109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.